Delving into the Latest Updates on Glimepiride with Synapse

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover relative bioavailability study of Glimepiride Oral Disintegration Strip 1 mg manufactured by: ZIM Laboratories, Nagpur, India, manufactured for: Sanofi Healthcare India Private Limited and Amaryl (Glimepiride) Tablet 1 mg Manufactured by Sanofi-Aventis Deutschland GmbH, Germany in healthy adult human subjects under fasting conditions. (Project Number: AZBE022406, Sponsor Study Code: BDR16756, Version: 1.0, Date: 09-APR-2024). - NIL

Start Date29 Nov 2024

Sponsor / Collaborator

Sanofi Healthcare India Pvt Ltd.

CTRI/2024/11/076291

/ Not yet recruitingNot Applicable

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover relative bioavailability study of Glimepiride Oral Disintegration Strip 1mg manufactured by: ZIM Laboratories, Nagpur, India, manufactured for: Sanofi Healthcare India PrivateLimited and Amaryl (Glimepiride) Tablet 1 mg Manufactured by Sanofi-Aventis Deutschland GmbH,Germany in healthy adult human subjects under fed conditions. (Project Number: AZBE022407, SponsorStudy Code: BDR17557, Version: 1.0, Date: 09-APR-2024) - NIL

Start Date29 Nov 2024

Sponsor / Collaborator

Sanofi Healthcare India Pvt Ltd.

100 Clinical Results associated with Glimepiride

Login to view more data

100 Translational Medicine associated with Glimepiride

Login to view more data

100 Patents (Medical) associated with Glimepiride

Login to view more data

2,780

Literatures (Medical) associated with Glimepiride

01 Dec 2025·Current Diabetes Reports

From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care

Review

Author: Dhingra, Atul ; Tuladhar, Jasmin ; Shakya, Santosh ; Shrestha, Dina

PURPOSE OF REVIEW:

This review aims to highlight the evolution and multifaceted benefits of modern sulfonylureas (SUs) in managing Type 2 Diabetes Mellitus (T2DM). It discusses their enhanced glycemic control, pleiotropic advantages, usage with other antidiabetic agents, safety, and tolerability, supporting their persistent relevance and effectiveness in diabetes care.

RECENT FINDINGS:

Recent findings indicate that modern SUs, like glimepiride, offer significant cardioprotective and renoprotective benefits along with their primary role in glycemic control. Additionally, they have also shown their anti-inflammatory effects, lipid-lowering properties, testosterone-enhancing effects, and neuroprotective effects in recent years. These findings support the broader therapeutic advantages of modern SUs beyond glucose lowering. Hence, many guidelines now recommend modern SUs as an add-on therapy to metformin. Modern sulfonylureas remain a vital component in T2DM management strategy due to their efficacy, safety profile, and cost-effectiveness. Their pleiotropic benefits, like cardiovascular, renal, anti-inflammatory, neuroprotective effects, etc., make them a comprehensive therapeutic option. Considering their efficacy and safety profile, SUs are expected to remain vital components of antidiabetic therapy, providing valuable benefits in managing T2DM in the long run.

01 Nov 2025·BIOCHEMICAL PHARMACOLOGY

Glimepiride overcomes acquired resistance to EGFR TKIs in lung cancer via the AMPK/ERK/MMP7 signaling pathway

Article

Author: Li, Min ; Li, Ling ; Li, Yan ; Zhang, Hu ; Han, Yi ; Huang, Xin

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) limits their clinical efficacy. Intratumoral heterogeneity and the coexistence of diverse resistance mechanisms make combination therapies focused on single molecules or pathways clinically ineffective. Here, our study demonstrated that glimepiride, a sulfonylurea drug, reversed and delayed acquired resistance to EGFR TKIs in lung cancer. Furthermore, glimepiride not only enhanced apoptosis in resistant cells but also suppressed cancer stemness. Mechanistically, glimepiride exerted these effects through AMPK activation, leading to subsequent suppression of the ERK/MMP7 signaling pathway. Our findings identify glimepiride as a promising therapeutic candidate for combination regimens in lung cancer treatment.

01 Sep 2025·Exploratory research in clinical and social pharmacy

Stevens-Johnson syndrome triggered by phenytoin in a patient with type 2 diabetes and seizures

Article

Author: Ansar, Mohammed ; Siddiqua, Aieman ; Mudaseer, Mohd ; Misbah Ul Haq, Mohammed

This case report describes a unique and severe instance of Stevens-Johnson syndrome (SJS) triggered by a combination of phenytoin, levetiracetam, glimepiride, and metformin in a patient with type 2 diabetes. SJS is a serious condition that affects the skin and mucous membranes and is often induced by various medications. The report underscores the critical importance of promptly identifying and managing SJS, as well as the need for careful monitoring of patients on multiple drugs, especially those with prior drug allergies. It also adds valuable insights to the existing literature on drug-induced SJS, emphasizing the role of a multidisciplinary approach in improving patient care and outcomes.

21

News (Medical) associated with Glimepiride

11 Aug 2025

·pharma.economictimes.indiatimes.com

Strong Emerging market sales drive Emcure Q1 FY26 revenue to ₹2100 Cr; net profit climbs 41%

Mumbai: In the first quarter of fiscal year 2025-26, Emcure Pharmaceuticals, revenue from operations stood at ₹2,101 crore with an year-on-year (YoY) increase of 15.72 per cent against the corresponding quarter. Net profit for the quarter reported a sharp jump of 40.76 per cent to ₹215 crore, up against ₹153 crore recorded in the year ago period. The company’s Earnings Before Interest, Taxes, Depreciation, and Amortisation ( EBITDA ) stood at ₹404 crore at a margin of 19.23 per cent. For the April-June period the company revenue from domestic business increased by 7.1 per cent to ₹995 crore. The company's strong revenue and profit growth is attributed with a sharp jump in emerging market sales which stood at ₹360 crore, up against ₹254 crore recorded in the year ago period. However, compared to the previous quarter, revenue reflects a sharp dip of 25.1%, down from ₹481 crore. During the period, the company sealed a distribution partnership with French-drugmaker, Sanofi to market its oral-anti diabetes portfolio in India. Under the agreement the portfolio includes Glimepiride marketed as Amaryl and Metformin marketed as Cetapin. Notably, the two brands stand as leading therapies in the oral anti-diabetic segment and are also used in combination with other molecules. Commenting on the results, Satish Mehta, CEO and MD Emcure Pharmaceuticals, said, The expanded Sanofi partnership positions us well in the fast growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth.” By Online Bureau ,

Financial StatementLicense out/in

17 Jul 2025

·www.echemi.com

Emcure Seals Exclusive Deal for Sanofi’s Oral Diabetes Brands Millions of Indian Patients to Benefit

Emcure Pharmaceuticals has signed an exclusive agreement to distribute and promote Sanofi’s oral anti-diabetes (OAD) medicines in India, a move set to impact millions living with type-2 diabetes. Under this arrangement, Sanofi will continue manufacturing its OAD brands—such as Glimepiride (Amaryl) and Metformin (Cetapin)—at its facilities, while Emcure gains the sole rights to market and distribute them across India. This partnership expands Emcure’s diabetes portfolio, promising broader access to these leading therapies for patients nationwide. CEO Satish Mehta highlighted that Sanofi’s trusted OAD medicines will now reach even more people, thanks to Emcure’s robust distribution network. Importantly, the deal will not involve any employee transfers between the two firms. The collaboration aims to create a comprehensive diabetes care offering, supporting those affected by the disease and strengthening both companies’ positions in the Indian pharmaceutical market.

License out/in

16 Jul 2025

·pharma.economictimes.indiatimes.com

Emcure to market Sanofi' Oral-Diabetes brands in India

Mumbai: Emcure Pharmaceuticals has inked an exclusive distribution agreement with the French drugmaker Sanofi to market the company’s oral anti-diabetes brands in India. Emcure Pharmaceuticals and Sanofi India limited (SIL) have entered into an exclusive distribution and promotion agreement for SIL’s oral anti-diabetic (OAD) products in India, effective immediately, the company said in a release. Under the agreement, Sanofi will manufacture its oral anti-diabetes (OAD) brands at its facilities in India and abroad, while Emcure will have exclusive rights to distribute and promote the portfolio in India. “This collaboration complements our existing diabetes portfolio , creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country,” said Satish Mehta CEO and MD, Emcure Pharmaceuticals Ltd. “With our strong distribution network in India, Sanofi’s trusted oral anti-diabetic medicines will be available to more patients who need them,” the CEO added. According to Emcure, "there will be no people transitioning between the two organizations in this arrangement." Currently, Sanofi oral-anti diabetes portfolio includes Glimepiride marketed as amaryl and Metformin marketed as Cetapin. Notably, the two brands stand as leading therapies in the oral anti-diabetic segment and are also used in combination with other molecules. Oral anti-diabetes medicines are indicated to patients with type-2 diabetes to stimulate insulin release, improve insulin sensitivity, or regulate glucose production by the liver. By Online Bureau ,

License out/in

100 Deals associated with Glimepiride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00593	Glimepiride	A10BB12	DB00222

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Sanofi-Aventis U.S. LLC	30 Nov 1995

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADA2024	Not Applicable	Diabetes Mellitus, Type 2	-	Glimepiride 1mg/Vildagliptin 50mg/Metformin 500mg	ilknptcucx(sqdqlqhzds) = Three mild hypoglycemic events were reported with the starting dose psngkjxgju (mjmbfbewpe )	-	14 Jun 2024
				Glimepiride 2mg/Vildagliptin 50mg/Metformin 1000mg
NCT05538819 (Pubmed \| Eur J Prev Cardiol)	Not Applicable	Diabetes Mellitus, Type 2 \| Chronic heart failure	-	Glimepiride treatment	lrdttlmirv(aazlpcftlf): HR = 0.47 (95% CI, 0.35 - 0.63) View more	-	27 Dec 2022
				No glimepiride treatment
NCT01794143 (GRADE, ASN2022)	Phase 3	Diabetes Mellitus, Type 2	-	Sitagliptin	mqhedprskf(asiwcbvtri) = nywawrzvqd kxfvopbaof (yiekmylxii, -2.20 to -1.86)	Negative	03 Nov 2022
				Glimepiride	mqhedprskf(asiwcbvtri) = ktnsqpeusk kxfvopbaof (yiekmylxii, -2.08 to -1.75)
NCT01167881 (EMPA-REG H2H-SU, Pubmed \| J Comp Eff Res)	Phase 3	Diabetes Mellitus, Type 2	1,549	Empagliflozin+metformin	jibjjqtgoa(hfvigypefk) = zdbdvvpppw xicgenxeyz (bifbbzfojv )	-	12 Feb 2021
EUCTR2017-000204-15-DK (EASD2020)	Phase 2	Maturity-Onset Diabetes of the Young, Type 3 Add-on	20	Glimepiride+Linagliptin	dmslcgmcng(bfaygjryzc) = tnrdulewih wjkyzgjbjr (gcbyjlygvs, -7.1 to -0.3) View more	Positive	24 Sep 2020
NCT01644500 (AWARD-CHN1, Pubmed)	Phase 3	Diabetes Mellitus, Type 2	737	Dulaglutide 1.5 mg	ueubflwbsr(nasoalsuxk) = aisvzccyuh ltfjmqmuqa (kbtyyanbyy ) View more	-	01 May 2020
				Dulaglutide 0.75 mg	ueubflwbsr(nasoalsuxk) = odlanepcaz ltfjmqmuqa (kbtyyanbyy ) View more
NCT01644500 (Pubmed)	Phase 3	Diabetes Mellitus, Type 2	572	Dulaglutide 1.5 mg	cbapflntfq(qursxfzkyb) = vzppocpnbh bbttliouqs (znydyavzet, ( - 0.74, to 0.32)) View more	Positive	01 Jan 2020
				Dulaglutide 0.75 mg	cbapflntfq(qursxfzkyb) = ryndltjrig bbttliouqs (znydyavzet, ( - 0.53, to 0.12))
JPRN-UMIN000026161 (EASD2019)	Not Applicable	Third line	-	Tofogliflozin 20 mg/day	rzawaapzci(rzkamohini) = Adverse events were observed in 27.3% patients in Tofogliflozin 20 mg/day and 29.0% in Glimepiride 0.5 mg/day. None of them were severe. There was one patient experienced hypoglycemia in Glimepiride 0.5 mg/day but none in Tofogliflozin 20 mg/day. trwlpwziva (xmbgyozxcr )	Positive	19 Sep 2019
				Glimepiride 0.5 mg/day
NCT02471404 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	939	Dapaglifozin (Dapaglifozin 10mg)	zrdweckfgl(ngjvinizmk) = tmiauqfzbc pshaslnhkd (lesmfdtgmg, 0.049) View more	-	26 Mar 2019
				Saxagliptin+Dapagliflozin (Saxagliptin 5mg and Dapagliflozin 10mg)	zrdweckfgl(ngjvinizmk) = votuprjdlq pshaslnhkd (lesmfdtgmg, 0.046) View more
NCT01644500 (Pubmed \| J Diabetes Res)	Phase 3	Diabetes Mellitus, Type 2	23	Once-weekly dulaglutide injection	pnnrucayyu(plmrtswcyg) = hpantmutkf chcioqyftf (vrsgdynios ) View more	-	01 Jan 2019
				Daily glimepiride	pnnrucayyu(plmrtswcyg) = porykpnwww chcioqyftf (vrsgdynios )